Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Connect with us

Hi, what are you looking for?

slide 3 of 2
THE BIZNOB – Global Business & Financial News – A Business Journal – Focus On Business Leaders, Technology – Enterpeneurship – Finance – Economy – Politics & LifestyleTHE BIZNOB – Global Business & Financial News – A Business Journal – Focus On Business Leaders, Technology – Enterpeneurship – Finance – Economy – Politics & Lifestyle

Breaking News

Breaking News

CEO claims Novavax eliminated $50 million, plans more.

People pose with syringe with needle in front of displayed Novavax logo in this illustration taken, ... People pose with syringe with needle in front of displayed Novavax logo in this illustration taken, December 11, 2021. REUTERS/Dado Ruvic/Illustration
People pose with syringe with needle in front of displayed Novavax logo in this illustration taken, ... People pose with syringe with needle in front of displayed Novavax logo in this illustration taken, December 11, 2021. REUTERS/Dado Ruvic/Illustration

Listen to the article now

In an interview on Wednesday, Novavax Inc (NVAX.O) CEO John Jacobs said the company slashed $50 million in expenses in the first quarter of 2023 and aimed to cut more.

Jacobs also said Novavax is in frequent conversations with the FDA about the design of its 2023 COVID-19 booster injection and expects it to be available by autumn.

Novavax, Inc. in Gaithersburg, Maryland, develops vaccinations for dangerous infectious illnesses. Company scientists generated experimental influenza, respiratory syncytial virus, Ebola, and other infectious illness vaccines before 2020.


Comment Template

You May Also Like

Business

Cricut Unveils New Crafting Machines: Faster, Cheaper, and More Accurate On February 27, 2025, Cricut, the beloved brand known for its innovative crafting machines,...

Business

**Excerpt:** Apple has unveiled a suite of new child safety features aimed at giving parents greater control over their kids’ app usage. Announced on...

Business

**Excerpt from "The Evolution of Legacy Media: Why It’s Not Dead Yet"** In a world dominated by digital platforms and instant news, Evan Leatherwood,...

Business

**Excerpt:** On February 27, 2025, newly confirmed FBI Director Kash Patel unveiled a groundbreaking proposal: a partnership between the FBI and the Ultimate Fighting...

Notice: The Biznob uses cookies to provide necessary website functionality, improve your experience and analyze our traffic. By using our website, you agree to our Privacy Policy and our Cookie Policy.

Ok